Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma

INCLUSION CRITERIA * Baseline measurements and evaluations must be obtained within 4 weeks of registration to the study. Abnormal PET scans will not constitute evaluable disease, unless verified by computed tomography (CT) scan or other appropriate imaging * At least 1 objective measurable disease parameter by Response Evaluation Criteria In Solid Tumors (RECIST) criteria * Unresectable locally advanced or metastatic angiosarcoma * ≤ 2 prior chemotherapeutic regimens for angiosarcoma * No prior paclitaxel, docetaxel, or bevacizumab for angiosarcoma (previous paclitaxel or docetaxel allowed if not given for angiosarcoma and more than 12 months has elapsed since last dose) * No evidence of other active malignancies other than carcinomas in-situ of the cervix or basal cell carcinoma of the skin within 6 months prior to registration * If history of deep venous thrombosis or pulmonary embolism, receiving a stable dose of anticoagulation therapy for at least 2 weeks prior to registration * Within 7 days prior to registration, use of any anti-platelet drugs, such as ticlopidine, clopidogrel, and cilostazol. The use of aspirin or other nonsteroidal anti-inflammatory drugs (NSAID) is allowed * ECOG performance status 0 to 2 * Patients must have adequate organ function as evidenced by the following laboratory studies (within 2 weeks prior to registration): * Serum creatinine ≤ 2.0 mg/dL * Total bilirubin ≤ 2.0 x upper limit of normal (ULN). If documented hepatic involvement, can be ≤ …